Japan Radiopharmaceuticals Market Size, Share, and COVID-19 Impact Analysis, By Radioisotopes (Iodine I, Technetium 99m, Fluorine 18, Gallium 68, Radium 223, Zirconium 89, and Others), By Application (Cancer, Neurology, Cardiology, and Others), and Japan Radiopharmaceuticals Market Insights, Industry Trend, Forecasts to 2035

Japan Radiopharmaceuticals Market Size Insights Forecasts to 2035

• The Japan Radiopharmaceuticals Market Size Was Estimated at USD 231.8 million in 2024
• The Market Size is Expected to Grow at a CAGR of Around 9.69 % from 2025 to 2035
• The Japan Radiopharmaceuticals Market Size is Expected to Reach USD 641.2 million by 2035

According to a Research Report Published by Spherical Insights & Consulting, the Japan Radiopharmaceuticals Market Size is anticipated to reach USD 641.2 million by 2035, growing at a CAGR of 9.69 % from 2025 to 2035. The radiopharmaceuticals market in Japan is driven by various factors, including rising prevalence of chronic diseases, increased demand for early and accurate diagnostics, advancements in nuclear imaging technologies, rise in the geriatric population, and government support.

Market Overview

Radiopharmaceuticals are a group of pharmaceutical drugs that contain radioactive isotopes. They are primarily employed in nuclear medicine for therapeutic and diagnostic imaging techniques. The commonly used isotopes in radiopharmaceuticals are Iodine I, technetium-99 m, fluorine-18, gallium-68, radium-223, and zirconium-89. Radiopharmaceuticals are commonly employed in imaging techniques like PET and SPECT to diagnose and detect conditions, including cancer, heart issues, and neurological disorders. Additionally, they are used therapeutically to provide concentrated radiation to treat diseases, including bone metastases and thyroid cancer. Radiopharmaceuticals are critical in modern healthcare because they provide accurate diagnostic information and focused therapies for specific diseases while minimizing radiation exposure to nearby healthy tissues. The Japanese radiopharmaceuticals market is experiencing rapid growth due to several factors. The rise in chronic diseases such as cardiovascular disorders and cancer due to a change in lifestyle fuels the demand for diagnostic and therapeutic radiopharmaceuticals, which is one of the major contributors to the market growth. Furthermore, as healthcare professionals and patients become more aware of the benefits of early disease identification and tailored therapy, this further contributes to the market growth. The rising inclination towards personalized radiopharmaceutical therapies is one of the key trends in this market. The development of novel radiopharmaceuticals presents a potential opportunity for market growth.

Report Coverage

This research report categorizes the market for the Japan radiopharmaceuticals market based on various segments and regions, and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Japan radiopharmaceuticals market. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Japan radiopharmaceuticals market.

Driving Factors

Cancer cases in Japan are expected to exceed 1.1 million by 2025, boosting demand for radiopharmaceuticals in diagnosis and therapy, according to the Japanese Society of Nuclear Medicine. Japan is one of the largest aging population countries, and the aging population is more susceptible to chronic diseases, which creates the demand for novel and accurate diagnostics ate treatments is further driving the market. Government support, including a 15% funding rise from 2021 to 2023 and streamlined regulations, is boosting Japan's radiopharmaceutical market growth and innovation. Additionally, technological advancements play a crucial role in market expansion.

Restraining Factors

Radiopharmaceutical manufacturing is expensive due to specialized equipment, complicated procedures, and expert personnel, which limits availability in resource-constrained healthcare settings. Additionally, strict constraints on radioactive material handling enhance costs and cause delays, limiting market entry and growth for novel radiopharmaceuticals.

Market Segmentation

The Japan radiopharmaceuticals market share is classified into radioisotopes and application.   

• The technetium 99m segment held a significant market share in 2024 and is expected to grow at a rapid CAGR during the forecast period.    

The Japan radiopharmaceuticals market is segmented by radioisotopes into Iodine I, technetium 99m, fluorine 18, gallium 68, radium 223, zirconium 89, and others. Among these, the technetium 99m segment held a significant market share in 2024 and is expected to grow at a rapid CAGR during the forecast period. This segmental growth is attributed to its widespread use in diagnostic imaging, particularly in cardiology and oncology. Additionally, its short half-life and excellent imaging capabilities contribute to the segmental growth.

• The cancer segment held the highest share in 2024 and is expected to grow at a significant CAGR during the forecast period.   

The Japan radiopharmaceuticals market is segmented by application into cancer, neurology, cardiology, and others. Among these, the cancer segment held the highest share in 2024 and is expected to grow at a significant CAGR during the forecast period. This is due to the rising prevalence of cancer and the increased adoption of radiopharmaceuticals in oncology.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Japan radiopharmaceuticals market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Tokyo Electron
• Mitsubishi Tanabe Pharma
• Fujifilm
• Sumitomo Dainippon Pharma
• Cardinal Health
• General Electric (GE Healthcare)
• Siemens Healthineers
• Alpha Fusion
• LinqMed
• Mevion Medical Systems
• PDRadiopharma
• Others

Recent Developments

• In December 2024, Eckert & Ziegler received Japanese approval for its GalliaPharm generator, expanding 68Ga-PSMA-11 access; Novartis Pharma K.K. managed distribution and safety key target audience

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at the Japan, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Japan radiopharmaceuticals market based on the below-mentioned segments:

Japan Radiopharmaceuticals Market, By Radioisotopes

• Iodine I
• Technetium 99m
• Fluorine 18
• Gallium 68
• Radium 223
• Zirconium 89
• Others

Japan Radiopharmaceuticals Market, By Application

• Cancer
• Neurology
• Cardiology
• Others